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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
“αS1-casein tryptic hydrolysate” and alleviation of psychological stress 
(ID 656, 1819, 4253) pursuant to Article 13(1) of Regulation (EC) 
No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,
 
3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to “αS1-casein tryptic hydrolysate” and alleviation of psychological stress. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The food constituents that are the subject of the health claims are “lactium milk protein hydrolysate”, 
“lactium-peptide compound” and “hydrolysat de protéines de lait: milk protein hydrolysate 
concentrated with 1,7 % of alphaS1 decapeptide (=lactium)”. In the context of the references 
provided, the Panel notes that the food constituent which is the subject of the health claims is a 
specific commercial preparation of αS1-casein tryptic hydrolysate. The Panel considers that the 
specific αS1-casein tryptic hydrolysate is sufficiently characterised.  
The claimed effects are “helps to calm mind”, “mental state and performance”, and “stress”. The 
target population is assumed to be the general population. In the context of the proposed wordings and 
from the references provided, the Panel assumes that the claimed effects refer to alleviation of 
psychological stress. The Panel considers that alleviation of psychological stress might be a beneficial 
physiological effect. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1443, EFSA-Q-2008-2552, EFSA-Q-2008-4963, 
adopted on 08 April 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Mental/Nervous System: Jacques Rigo, Astrid Schloerscheidt, Barbara Stewart-Knox, Sean (J.J.) Strain, and Peter 
Willatts. 
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No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of “αS1-casein tryptic hydrolysate” and alleviation of 
psychological stress. 
KEY WORDS 
αS1-Casein tryptic hydrolysate, psychological stress, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C.  
ASSESSMENT 
1. Characterisation of the food/constituent (ID 656, 1819, 4253) 
The food constituents that are the subject of the health claims are “lactium milk protein hydrolysate”, 
“lactium-peptide compound” and “hydrolysat de protéines de lait: milk protein hydrolysate 
concentrated with 1,7 % of alphaS1 decapeptide (=lactium)”.  
In the context of the references provided, the Panel notes that the food constituent which is the subject 
of the health claims is a specific commercial preparation of αS1-casein tryptic hydrolysate. The milk 
protein hydrolysate is released during the tryptic breakdown of the milk protein αS1-casein. The main 
peptide in the specific αS1-casein tryptic hydrolysate that is the subject of the health claim is αS1-CN 
(f91-100), a decapeptide called α-casozepine (Miclo et al., 2001). 
The Panel considers that the food constituent, the specific αS1-casein tryptic hydrolysate, which is the 
subject of the health claim, is sufficiently characterised. 
2. Relevance of the claimed effect to human health (ID 656, 1819, 4253) 
The claimed effects are “helps to calm mind”, “mental state and performance”, and “stress”. The 
Panel assumes that the target population is the general population. 
In the context of the proposed wordings and from the references provided, the Panel assumes that the 
claimed effects refer to alleviation of psychological stress. Psychological stress can be measured by 
established methods. 
The Panel considers that alleviation of psychological stress might be a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect (ID 656, 1819, 4253) 
Six references were provided for the scientific substantiation of the claim, including two posters with 
insufficient information regarding the study design, methodology and statistical analyses for a 
complete scientific evaluation. Another reference, which was not accessible to the Panel after every 
reasonable effort was made to retrieve it, was an unpublished double-blind, placebo-controlled, 
parallel trial using αS1-casein tryptic hydrolysate. One reference reported on in vitro and animal 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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studies where “αS1-casein tryptic hydrolysate” was administered via intra-peritoneal injections, which 
is not a relevant route for human nutrition. The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claim. 
A double-blind, randomised controlled trial (RCT) was conducted in 42 healthy males who ingested 
three times, 12 hours apart, two capsules containing either 200 mg of “αS1-casein tryptic hydrolysate” 
(total=400 mg) or a placebo (bovine skimmed milk powder) (Messaoudi et al., 2005). On the test day, 
two hours after the administration of the third dose of “αS1-casein tryptic hydrolysate”, subjects 
undertook the Stroop Test and, after a 30-min rest, a Cold Pressor Test (CPT). Outcome measures 
were changes in systolic and diastolic blood pressure, heart rate and plasma cortisol concentrations in 
response to the Stroop and/or the CPT. The Panel notes that changes in physiological parameters are 
not direct measures of psychological stress, and are not sufficient on their own to indicate an 
alleviation of psychological stress. The Panel considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim. 
In a double-blind, cross-over RCT, 63 females who reported at least one of the symptoms of anxiety, 
sleep problems and general fatigue received 150 mg/day of “αS1-casein tryptic hydrolysate” and a 
placebo (bovine skimmed milk powder) for 30 days each with a three-week wash-out period in 
between (Kim et al., 2007). The outcome measure was a new 44-item questionnaire developed by 
combining two existing anxiety scales (Hamilton Anxiety Scale and Ferreri Anxiety Rating Diagram), 
and was assessed at days 0, 15 and 30 of each intervention period. The Panel notes that no 
information was provided on the validity and reliability of this novel questionnaire to directly and 
specifically measure psychological stress, and considers that no conclusions can be drawn from this 
study for the scientific substantiation of the claim.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of “αS1-casein tryptic hydrolysate” and alleviation of psychological stress. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, the specific αS1-casein tryptic hydrolysate, which is the subject of the 
health claim, is sufficiently characterised. 
 The claimed effects are “helps to calm mind”, “mental state and performance”, and “stress”. 
The target population is assumed to be the general population. Alleviation of psychological 
stress might be a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
“αS1-casein tryptic hydrolysate” and alleviation of psychological stress. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1443, 
EFSA-Q-2008-2552, EFSA-Q-2008-4963). The scientific substantiation is based on the information 
provided by the Member States in the consolidated list of Article 13 health claims and references that 
EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
“αS1-Casein tryptic hydrolysate” and alleviation of psychological stress 
 
7 EFSA Journal 2011;9(6):2273 
REFERENCES  
Kim JH, Desor D, Kim YT, Yoon WJ, Kim KS, Jun JS, Pyun KH and Shim I, 2007. Efficacy of 
alphas1-casein hydrolysate on stress-related symptoms in women. European Journal of Clinical 
Nutrition, 61, 536-541. 
Messaoudi M, Lefranc-Millot C, Desor D, Demagny B and Bourdon L, 2005. Effects of a tryptic 
hydrolysate from bovine milk alphaS1-casein on hemodynamic responses in healthy human 
volunteers facing successive mental and physical stress situations. European Journal of Nutrition, 
44, 128-132. 
Miclo L, Perrin E, Driou A, Papadopoulos V, Boujrad N, Vanderesse R, Boudier JF, Desor D, Linden 
G and Gaillard JL, 2001. Characterization of alpha-casozepine, a tryptic peptide from bovine 
alpha(s1)-casein with benzodiazepine-like activity. FASEB Journal, 15, 1780-1782. 
 
 
“αS1-Casein tryptic hydrolysate” and alleviation of psychological stress 
 
8 EFSA Journal 2011;9(6):2273 
APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
6 OJ  L12, 18/01/2007 
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).   
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
“αS1-Casein tryptic hydrolysate” and alleviation of psychological stress 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
“αS1-Casein tryptic hydrolysate” and alleviation of psychological stress 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to “αS1-casein tryptic hydrolysate”, including conditions of 
use from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
656 Lactium milk protein 
hydrolysate 
helps to calm mind 
Clarification provided 
On the basis of stabilizing 
blood pressure and lowering 
cortisol levels in plasma, 
these results suggest an 
antistress profile of this 
hydrolysate in human 
subjects.  'helps to calm mind 
Is believed to play a role in 
stress situation e.g. helps to 
keep normal or slightly 
increased blood pressure in 
critical situations   
helps to calm and harmonize 
mind helps organism to adapt 
for emotional stress, physical 
effort 
Conditions of use 
- 150 mg of lactium per day 
ID Food or Food constituent Health Relationship Proposed wording 
1819 Lactium-peptide compound Mental state and 
performance 
Regulates stress hormone 
secretion. 
Stabilises vital functions 
during stress. 
Conditions of use 
- Food supplement with 150mg of Lactium-peptide compound in the daily dose. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
4253 Hydrolysat de protéines de lait: 
milk protein hydrolysate 
concentrated with 1,7 % of 
alphaS1 decapeptide 
(=Lactium) 
Stress Can help with better resisting 
the stress 
Conditions of use 
- 150 or 300 mg per day 
No clarification provided by Member States 
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GLOSSARY AND ABBREVIATIONS 
CPT  Cold pressor test 
RCT  Randomised controlled trial 
